Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Scancell to receive patent protection for key cancer platform

Once formally granted, the patent will provide protection for Scancell’s pipeline of Moditope vaccines
patents
This is a key case for the company as we progress development of our Moditope platform - said chief executive Cliff Holloway

Scancell Holdings Plc (LON:SCLP) said the European Patent Office intends to grant the company’s patent application for the Moditope immunotherapy platform.

Once formally granted the patent will provide protection for Scancell’s pipeline of Moditope vaccines that could help revolutionise the way cancer is treated.

READ: Scancell-led team short-listed for award

The patent will cover all major areas in Europe, while similar filings have been made in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US.

"By confirming its intention to grant this patent application, the European Patent Office has continued to uphold the validity of Scancell's expanding patent estate,” said chief executive Cliff Holloway. 

“This is a key case for the company as we progress development of our Moditope platform and provides further protection for Scancell's innovative cancer vaccine technologies."

View full SCLP profile View Profile

Scancell Holdings Plc Timeline

Related Articles

pills
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use